Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.
Min Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rui Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sameer Doshi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Steven Kathman
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Per Olsson Gisleskog
Consultant or Advisory Role - Amgen
Sarita Dubey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yizhou Jiang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ross C. Donehower
Research Funding - Amgen
Timothy Iveson
Research Funding - Amgen
Other Remuneration - Amgen
Elwyn Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen